title: Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
abstract: Low-dose cisplatin and 5-fluorouracil (LDPF) chemotherapy with daily radiotherapy (RT) is used as an alternative chemoradiotherapy regimen for locally advanced esophageal carcinoma. We evaluated whether RT plus LDPF chemotherapy had an advantage in terms of survival and/or toxicity over RT plus standard-dose cisplatin and 5-fluorouracil (SDPF) chemotherapy in this study. This multicenter trial included esophageal cancer patients with clinical T4 disease and/or unresectable regional lymph node metastasis. Patients were randomly assigned to receive RT (2 Gy/fraction, total dose of 60 Gy) with SDPF (arm A) or LDPF (arm B) chemotherapy. The primary endpoint was overall survival (OS). A total of 142 patients (arm A/B, 71/71) from 41 institutions were enrolled between April 2004 and September 2009. The OS hazard ratio in arm B versus arm A was 1.05 (80% confidence interval, 0.78-1.41). There were no differences in toxicities in either arm. Arm B was judged as not promising for further evaluation in the phase III setting. Thus, the Data and Safety Monitoring Committee recommended that the study be terminated. In the updated analyses, median OS and 3-year OS were 13.1 months and 25.9%, respectively, for arm A and 14.4 months and 25.7%, respectively, for arm B. Daily RT plus LDPF chemotherapy did not qualify for further evaluation as a new treatment option for patients with locally advanced unresectable esophageal cancer. This study was registered at the UMIN Clinical Trials Registry as UMIN000000861.
authors: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan.
authors: Masayuki
authors: M
authors: Shinoda
authors: Nobutoshi
authors: N
authors: Ando
authors: Ken
authors: K
authors: Kato
authors: Satoshi
authors: S
authors: Ishikura
authors: Hoichi
authors: H
authors: Kato
authors: Yasuhiro
authors: Y
authors: Tsubosa
authors: Keiko
authors: K
authors: Minashi
authors: Hiroshi
authors: H
authors: Okabe
authors: Yusuke
authors: Y
authors: Kimura
authors: Tatsuyuki
authors: T
authors: Kawano
authors: Shin-Ichi
authors: S
authors: Kosugi
authors: Yasushi
authors: Y
authors: Toh
authors: Kenichi
authors: K
authors: Nakamura
authors: Haruhiko
authors: H
authors: Fukuda
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D005472:Fluorouracil
keywords: Chemoradiotherapy; esophageal squamous cell carcinoma; randomized trial; survival; toxicity
references: J Clin Oncol. 1999 Sep;17(9):2915-21
references: 10561371
references: Jpn J Clin Oncol. 2012 Sep;42(9):807-12
references: 22811410
references: World J Surg. 2001 Mar;25(3):279-84
references: 11343176
references: Dis Esophagus. 2001;14(3-4):197-201
references: 11869319
references: Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):134-9
references: 12007951
references: Br J Cancer. 2003 Jan 13;88(1):18-24
references: 12556953
references: Int J Clin Oncol. 2004 Jun;9(3):149-53
references: 15221597
references: Radiology. 1983 Feb;146(2):433-8
references: 6849089
references: Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5
references: 3466165
references: Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1735-8
references: 2822636
references: Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):967-72
references: 2170309
references: Cancer Chemother Pharmacol. 1990;27(1):55-9
references: 2245493
references: Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):351-5
references: 1846848
references: Cancer. 1991 Jun 1;67(11):2748-52
references: 1851046
references: N Engl J Med. 1992 Jun 11;326(24):1593-8
references: 1584260
references: J Clin Oncol. 1994 Sep;12(9):1814-20
references: 8083705
references: Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):921-7
references: 7860407
references: J Clin Oncol. 1997 Jan;15(1):277-84
references: 8996153
references: Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):29-34
references: 9747816
references: Jpn J Clin Oncol. 2004 Oct;34(10):615-9
references: 15591460
references: World J Surg. 2005 Jan;29(1):25-30; discussion 30-1
references: 15599735
references: Int J Clin Oncol. 2007 Feb;12(1):25-30
references: 17380437
references: Dis Esophagus. 2009;22(6):482-9
references: 19191850
references: Int J Clin Oncol. 2012 Apr;17(2):105-11
references: 21667354
references: J Clin Oncol. 2000 Apr;18(7):1458-64
references: 10735893